Beren Therapeutics raised $300 million as it moves adrabetadex toward FDA review under priority review. The company’s funding arrives at a critical point for adrabetadex, its drug intended for children with fatal rare diseases, and signals continued capital access for pediatric gene therapy development. The financing is positioned alongside the FDA’s acceptance of the new drug application and the associated expedited timeline. Beren is using the runway to support the regulatory process and ongoing clinical and manufacturing preparations. For the sector, the round reinforces demand for mechanism-specific pediatric therapies and highlights how priority review status can be a catalyst for large biotech fundraising.